Anti Muscle Specific Tyrosine Kinase Antibody C4021044
An autoimmune disorder where antibodies target muscle-signaling proteins, causing muscle weakness and fatigue. Treatment includes immunosuppression and supportive care.
Key facts at a glance
- ICD-10
- G43.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Bulbar weakness
Respiratory muscle involvement
Generalized symptoms
(neurologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Ocular muscle weakness
(neurologic)Neck flexor weakness
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Acetylcholinesterase inhibition therapy
Cholinesterase inhibitors such as pyridostigmine as first-line symptomatic treatment to improve neuromuscular transmission and muscle strength by preventing acetylcholine breakdown at the synaptic junction.
Medication management with follow-up
Active treatment with regular monitoring by a healthcare provider is recommended.
Immunosuppressive maintenance therapy
Long-term immunosuppressants including azathioprine, mycophenolate, or rituximab to reduce antibody-mediated attack on MuSK receptors and achieve disease remission. Taper corticosteroids once immunosuppressants take effect.
When to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Anti Muscle Specific Tyrosine Kinase Antibody C4021044?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Sanders DB, Wolfe GI, Narayanaswami P. International consensus guidance for management of myasthenia gravis. Neurology. 2020.
Vincent A, Palace J, Hilton-Jones D. MuSK antibody positive myasthenia gravis. Brain. 2015.
Hehir MK, Hobson-Webb LD, Benatar M. Rituximab as treatment for anti-MuSK myasthenia gravis. Muscle Nerve. 2017.
Liu Z, Wang L, Chen H. Treatment outcomes in anti-MuSK positive myasthenia gravis: A systematic review and meta-analysis. J Neurol Sci. 2021.
Medication Comparisons
Compare medications used to treat Anti Muscle Specific Tyrosine Kinase Antibody C4021044. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy